NCT06717022招募中不适用
A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年5月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Dose Limiting Toxicities (DLTs) occurence
研究概览
简要总结
Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand and sign a written informed consent document；
- •Age ≥18 years old, male or female；
- •Histopathological confirmed advanced or metastatic solid tumors failed to at least standard first-line therapy or initially diagnosed advanced solid tumors that have no National Comprehensive Cancer Network (NCCN ）guideline recommended standard first-line therapy；
- •Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced/metastatic solid tumor (positive tumor MSLN expression (tumor MSLN positive (IHC 2+) confirmed by histology or pathology));
- •At least one measurable lesion at baseline per RECIST version 1.1；
- •The expected survival time is more than 12 weeks;
- •ECOG(American Eastern Oncology Consortium) 0-1 points;
- •The function of important organs is basically normal;
- •The investigator determines that the patient must have fully recovered from previous treatment toxicity to ≤ grade 1, except in the following cases: a. Hair loss; b. Pigmentation; c. Long-term toxicity caused by radiotherapy, which could not be recovered according to the investigators; d. Platinum induced grade 2 or lower neurotoxicity (CTCAE 5.0);
- •Subjects agree to use reliable and effective contraceptive methods for contraception within
- •6 months after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception).
排除标准
- •Received any experimental drug treatment or used experimental devices within 28 days;
- •Received anti-tumor therapy such as chemotherapy and targeted therapy within 4 weeks;
- •Received cell therapy products other than MSLN targets within 1 month;
- •Patients who have previously received other cell therapy products should be tested for RCL(Replication Competent Retrovirus ) during the screening period if any test result is positive;
- •Received chemotherapy other than lymphocyte clearance chemotherapy within 14 days prior to CHT102 infusion;
- •Received systemic corticosteroid therapy at doses greater than 10 mg/day prednisone (or equivalent doses of other corticosteroids) within 2 weeks；
- •Patients receiving oral or intravenous anticoagulant therapy within 7 days prior to CHT102 cell infusion;
- •Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;
- •Patients with immune deficiency or autoimmune diseases, or who require immunosuppressants;
- •Vaccination within 14 days of study enrollment, or who required live vaccine immunization during the study period;
- •Active/symptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging evidence of progression ≥ 4 weeks after the end of treatment before they can be enrolled;
- •Serious or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, liver and kidney insufficiency or metabolic disease, central nervous system disease, etc;
- •Have any of the following heart conditions:
- •New York Heart Association (NYHA) stage III or IV congestive heart failure;
- •Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;
- •Clinically significant ventricular arrhythmia,
- •echocardiography showed cardiac ejection fraction<50%, QTc (male)>450 ms，QTc (female)>470 ms；;
- •Pregnant, lactating, or breastfeeding females;
- •Patients with poor control of thoracoabdominal water;
- •Other investigators deem it inappropriate to participate in the study.
研究组 & 干预措施
CHT102 allogeneic CAR T cells
Experimental
In the dose escalation phase of this study, one alternative dose and 4 dose groups (calculated by the number of CAR-positive T cells) were planned, each treatment lasted 28 days, and UCAR-T cells were transfused three times, respectively on D1, D5, and D9. The single dose within the group was fixed, and the dose between the groups was escalating dose. Each infusion dose was 2.5×106/kg (optional), 5×106/kg, 1×107/kg, 2×107/kg, and 3×107/kg, with a dose error of 20% allowed.
干预措施: CHT102 allogeneic CAR T cells (Biological)
结局指标
主要结局
Dose Limiting Toxicities (DLTs) occurence
时间窗: Baseline up to 28 days after U CAR-T infusion
Adverse events assessed according to NCI-CTCAE v5.0 criteria
次要结局
- Objective Response Rate(At 4 weeks, and overall)
- Progression-free survival(Assessed up to 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyAdvanced Gynecological MalignancyNCT06654440Shanghai Hengrui Pharmaceutical Co., Ltd.100
Unknown
早期 1 期
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerOvarian CancerNCT03814447Shanghai 6th People's Hospital10
Unknown
2 期
Investigator's Initiated Phase II Study for Pancreatic Cancer PatientsPancreatic CancerNCT01659502Tiltan Pharma Ltd.10
Unknown
2 期
Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological MalignanciesMalignant Trophoblastic TumorOvarian CancerCervical CancerNCT05342506Peking Union Medical College Hospital30
尚未招募
早期 1 期
Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal MetastasesGastric CancerNCT06224738First People's Hospital of Hangzhou9